• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TYP
Click for more information
2.63% 3.9¢

TRYPTAMINE THERAPEUTICS LIMITED - Charts / Financials

Market Cap $47.83M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology... Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Day
Open 3.8¢   Day High 3.9¢   Day Low 3.8¢
Daily Volume 182443
Bids   Sellers
Number Price Volume   Number Price Volume
2 3.9¢ 206403   3 4.0¢ 215000

Directors & Senior Management

Mr. Jason Carroll Chief Executive Officer, Director
Mr. Hamish George Chief Financial Officer
Mr. David Franks Company Secretary
Mr. Mark Davies Non-Executive Independent Chairman of the Board
Mr. Clarke Barlow Non-Executive Director
Mr. Gage Jull Non-Executive Director
Mr. Peter Molloy Non-Executive Director
Mr. Christopher Ntoumenopoulos Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
3.9¢ 		Change
0.001(2.63%) 		Mkt cap ! $47.83M
Open High Low Value Volume
3.8¢ 3.9¢ 3.8¢ $7.062K 182.4K

Buyers (Bids)

No. Vol. Price($)
2 206403 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 215000 3
View Market Depth
Last trade - 15.59pm 17/01/2025 (20 minute delay) ?

Top Stories

Week 3 Wrap: Trump 2.0 kicks off next week (where is RFK?); US CPI reassures markets; Israel-Hamas ceasefire and the Red Sea

It will be a most interesting day to wake up on the 22nd in Australia. We will either wake up to a world where the President of the United States has begun arresting journalists, Democratic politicians and other anti-Trump advocates @ or a world where he hasn’t. That two-sided coi...
Lightning Minerals ready to drill with spodumene confirmed in Brazil Lightning Minerals Ltd has confirmed the presence of spodumene mineralisation through Raman spectrographic analysi
Lynas sales revenues up in Q2 of FY 2025, but lower production fuels share price slump Lynas Rare Earths Ltd has seen its share price drop 5.5% after releasing quarterly activities report in which it noted lower production
ASX Market Open: Tech stocks pull US indexes lower, reflected in weak Aussie opening | January 17, 2025 The Australian market is set to open virtually flat today, weighed down by falls on all three US bourses, as major tech stocks were lower
GTI progresses scoping study and other assessment work at Lo Hema GTI Energy Ltd has started drilling for the development of groundwater monitoring wells at the Lo Hema uranium project in Wyoming
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.